MediWound Ltd. MDWD
Nov 12, 2026, 2:56 PM EST
- YTD
- -28.71%
- 1 year
- -27.77%
- Market cap
- 188.94M
- Revenue (ttm)
- 20.14M
- Profit margin
- -99.17%
- EPS (ttm)
- -2.17
- Shares out
- 10.79M
- Forward P/E
- -7.96
- YTD return
- -28.71%
- 1-year return
- -27.77%
- Volume
- 172.38K
- Avg volume
- 110.95K
- Open
- 12.60
- Previous close
- 13.82
- Day's range
- 12.50 – 13.53
- 52-week range
- 11.85 – 19.37
- Beta
- 0.84
- Price target
- 29.00 (+120.4%)
5D -0.29 (-2.17%)
Key statistics
- Enterprise value
- 138.07M
- PEG ratio
- 0.00
- Price / sales
- 9.47
- Price / book
- 5.16
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 6.10%
- Free cash flow
- -8.42M
- Total cash
- 29.21M
- Total debt
- 6.36M
- Return on equity
- -75.66%
- Short % of float
- 6.43%
- 50-day average
- 17.27
- 200-day average
- 17.21
Analyst view
- Target (low)
- 25.00
- Target (mean)
- 29.00
- Target (high)
- 36.00
- Strong buy2
- Buy2
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.55667.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 26, 2024 | Sep 1, 2024 | -0.48 | -0.98 | -0.50 | -104.17% |
| Aug 14, 2024 | Jun 1, 2024 | -0.42 | -0.68 | -0.26 | -61.90% |
| May 29, 2024 | Mar 1, 2024 | -0.40 | -0.39 | +0.01 | +2.50% |
| Mar 21, 2024 | Dec 1, 2023 | -0.23 | -0.19 | +0.04 | +17.39% |
| Nov 21, 2023 | Sep 1, 2023 | -0.45 | -0.24 | +0.21 | +46.67% |
| Aug 15, 2023 | Jun 1, 2023 | -0.41 | 0.10 | +0.51 | +124.39% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 27, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Oct 11, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 15, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jul 16, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 30, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Mar 22, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About MediWound Ltd.
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Israel
- Website
- mediwound.com
News
What MediWound (MDWD) Said on Its Q3 Earnings Call 
MediWound Ltd. (MDWD) Q3 2026 Earnings Call Transcript 
MediWound Q3 2026 Earnings Call Transcript 
MediWound (MDWD) Reports Q3 Loss, Lags Revenue Estimates 
CORRECTION: MediWound Q3 EPS $(0.65) Beats $(0.71) Estimate, Sales $3.600M Miss $6.728M Estimate 
MediWound Q3 EPS $(0.46) Beats $(0.71) Estimate, Sales $3.600M Miss $6.728M Estimate 
MediWound Reports Third Quarter 2026 Financial Results and Provides Corporate Update 
MediWound Announces Closing of $17.25 Million Bought Deal Offering of Ordinary Shares 
MediWound (MDWD) Moves 6.1% Higher: Will This Strength Last? - MediWound Announces $15M Bought Deal Offering Of 1.2M Shares At $12.50/Share
Your note
Sign in to keep a note on MDWD — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Investor AB | 6.83% | 872,093 | 15.41M | Sep 29, 2024 |
| Yelin Lapidot Holdings Management Ltd. | 5.88% | 750,743 | 13.27M | Sep 29, 2024 |
| Rosalind Advisors, Inc. | 4.92% | 628,050 | 11.10M | Sep 29, 2024 |
| Blackrock Inc. | 3.39% | 432,996 | 7.65M | Sep 29, 2024 |
| Balyasny Asset Management LLC | 1.30% | 165,736 | 2.93M | Sep 29, 2024 |
| Sargent Investment Group, LLC | 0.92% | 117,192 | 2.07M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Russell 2000 ETF | 1.62% | 206,380 | 3.65M | Oct 30, 2024 |
| ARK ETF Tr-ARK Israel Innovative Technology ETF | 0.91% | 115,765 | 2.05M | Oct 30, 2024 |
| Fidelity Small Cap Index Fund | 0.64% | 81,744 | 1.44M | Aug 30, 2024 |
| iShares Russell 2000 Growth ETF | 0.55% | 70,150 | 1.24M | Oct 30, 2024 |
| Vanguard Russell 2000 Index Fund | 0.25% | 32,376 | 572.08K | Aug 30, 2024 |
| 1290 Fds-1290 Essex Small Cap Growth Fd | 0.17% | 21,233 | 375.19K | Jul 30, 2024 |